S. Stenglein

Omalizumab (Xolair) in children with seasonal allergic rhinitis: Leukotriene release as a potential in vitro parameter to monitor therapeutic effects

U. Wahn, E. Hamelmann, S. Zielen, 2007, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

The co‐seasonal application of anti‐IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children

T. Keil, U. Wahn, E. Hamelmann, 2004, Allergy.

Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co‐morbid seasonal allergic asthma

K. Bergmann, U. Wahn, E. Hamelmann, 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.